Matinas Biopharma (MTNB) vs SciSparc (SPRC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Matinas Biopharma is the larger company by market cap ($2.7 million vs $2.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | MTNB | SPRC |
|---|---|---|
| Share price | $2.79 | $4.43 |
| Market cap | $2.73M | $2.57M |
| 1-day change | +0.72% | -4.53% |
| P/E ratio (TTM) | — | 0.02 |
| EPS (TTM) | $-17.55 | $248.24 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $28.95 | $43.65 |
| 52-week low | $2.27 | $2.98 |
| Distance from 52-week high | -90.36% | -89.85% |
| Average volume | 405.99K | 180.20K |
| Shares outstanding | 979.52K | 580.97K |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
MTNB vs SPRC FAQ
Which is bigger, Matinas Biopharma or SciSparc?
Matinas Biopharma (MTNB) is larger, with a market capitalization of $2.73M compared with $2.57M for SciSparc (SPRC).
Are Matinas Biopharma and SciSparc in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.